Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Shanghai Haohai Biological Technology Co., Ltd.
  6. Summary
    6826   CNE100001W69

SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.

(6826)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
98 85 78 82.7 83.8 Last
1473000 2218900 2258500 1714200 1444300 Volume
+0.51% -13.27% -8.24% +6.03% +1.33% Change
Estimated financial data (e)
Sales 2021 1 883 M 292 M 292 M
Net income 2021 465 M 72,0 M 72,0 M
Net cash position 2021 3 276 M 507 M 507 M
P/E ratio 2021 31,5x
Yield 2021 0,82%
Sales 2022 2 305 M 357 M 357 M
Net income 2022 602 M 93,3 M 93,3 M
Net cash position 2022 3 488 M 540 M 540 M
P/E ratio 2022 25,4x
Yield 2022 0,96%
Capitalization 39 849 M 5 123 M 6 170 M
EV / Sales 2021 19,4x
EV / Sales 2022 15,8x
Nbr of Employees 1 374
Free-Float 33,9%
More Financials
Company
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical... 
More about the company
Ratings of Shanghai Haohai Biological Technology Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
07/21ARCSCAN, INC. : Signs Definitive Agreement for $11.15 Million Preferred Series B..
PR
07/21ArcScan, Inc. announced that it expects to receive $11.15 million in funding ..
CI
06/28SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Expects Huge Jump in First-Half Profit
MT
06/25Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidat..
CI
06/11Shanghai Haohai Biological Technology Co., Ltd. Approves Profit Distribution ..
CI
05/23SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Haohai Biotech Boosts Ownership in UK-Bas..
MT
05/21Shanghai Haohai Biological Technology Co., Ltd. entered into a share purchase..
CI
05/10SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Notice of 2021 first h shareholders' clas..
PU
05/10SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : (1) work report of the board for 2020 (2)..
PU
05/10SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Form of proxy for the 2021 first h shareh..
PU
05/10SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Form of proxy for the 2020 annual general..
PU
04/26SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Biotech Swings to Profit in First Quarter..
MT
04/23Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for ..
CI
03/27SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Announcement of annual resultsfor the yea..
PU
03/27SHANGHAI HAOHAI BIOLOGICAL TECHNOLOG : Continuing connected transactions-spray p..
PU
More news
News in other languages on SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.

- No features available -

More news
Chart SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
Duration : Period :
Shanghai Haohai Biological Technology Co., Ltd. Technical Analysis Chart | 6826 | CNE100001W69 | MarketScreener
Technical analysis trends SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 83,80 CNY
Average target price 106,08 CNY
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Jian Ying Wu General Manager & Executive Director
Min Jie Tang Chief Financial Officer & Executive Director
Yong Tai Hou Chairman
Yuan Zhong Liu Chairman-Supervisory Board
Chang Zheng Wei Member-Supervisory Board
Sector and Competitors